Clinical Trial Update: Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating orelabrutinib combined with R-CDOP for high CNS-relapse risk DLBCL patients (CNS-IPI defined).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• R-CDOP

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN